Advertisement
Advertisement
LRMR
Larimar Therapeutics, Inc. Common Stock
3.58
USDSponsored
-0.31
-7.97%
May 15, 15:59 UTC -4
Closed
After-Market
3.67
+0.08
+2.37%
LRMR Earnings Reports
Positive Surprise Ratio
LRMR beat 26 of 39 last estimates.
67%
Next Report
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.41
Implied change from Q1 26 (Revenue/ EPS)
--
/+32.26%
Implied change from Q2 25 (Revenue/ EPS)
--
/--
Larimar Therapeutics, Inc. Common Stock earnings per share and revenue
On May 14, 2026, LRMR reported earnings of -0.31 USD per share (EPS) for Q1 26, beating the estimate of -0.54 USD, resulting in a 43.19% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.75% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.41 USD, with revenue projected to reach -- USD, implying an increase of 32.26% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were Larimar Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Larimar Therapeutics, Inc. Common Stock reported EPS of -$0.31, beating estimates by 43.19%, and revenue of $0.00, 0% as expectations.
How did the market react to Larimar Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.75%, changed from $4.00 before the earnings release to $3.97 the day after.
When is Larimar Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Larimar Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Larimar Therapeutics, Inc. Common Stock is expected to report EPS of -$0.41 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement